Nusinersen not checked
Biogen · BIIB058 · ISIS 396443
FollowEvery change as it happens, and a Monday email
Trials
2 active
15 in total · 4 in the EU
What this is
- How it works
- A short strand of genetic material that blocks one gene's message, so the body makes less of one protein.Survival Motor Neuron-2-directed RNA Interaction; Antisense Oligonucleotide FDA class
- Tested for
- Spinal Muscular Atrophy, Muscular Atrophy, Spinal
- Main trialPhase 3
- “In this study, researchers will learn more about the use of a higher dose of nusinersen (BIIB058) in participants with spinal muscular atrophy (SMA). This study will focus on teenagers and adults who are unable to walk on their own and who have previously taken another drug for SMA called risdiplam. The main goal of this study is to learn about the effect of high dose (HD) nusinersen on muscle and movement ability (motor function) in SMA. The main question that researchers want to answer is: \- How do the scores of a movement test called the Revised Upper Limb Module change from the start…”In the company’s words, NCT05067790 on ClinicalTrials.gov
- Other names
- BIIB058 · ISIS SMNRx · ISIS 396443 · Spinraza · IONIS-SMN Rx · Sprinraza
Other drugs for Spinal Muscular Atrophy
- BMS-986365Celgene · Phase 3
- RinzimetostatORIC Pharmaceuticals · Phase 3
- SalanersenBiogen · Phase 3
- ApitegromabScholar Rock · Phase 3
- Taldefgrobep alfaBiohaven · Phase 3
- Vesemnogene lantuparvovecLantu Biopharma · Phase 1/2
Coming up2
- 24 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Sep 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials15
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 24 Sep 2027 | A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) | |
| Phase 1Recruiting | 30 Sep 2027 | A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) | |
| Phase 4Completed | 9 Oct 2025 | A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND) | |
| Phase 3Terminated | 21 Nov 2016 | A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy | |
| Phase 3Completed | 20 Feb 2017 | A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) | |
| Phase 3Completed | 21 Aug 2023 | A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies | |
| Phase 3Completed | 21 Feb 2024 | Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy | |
| Phase 3Completed | 30 Jul 2026 | A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD) | |
| Phase 2Completed | 21 Aug 2017 | A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA) | |
| Phase 2Terminated | 24 Sep 2018 | A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA). | |
| Phase 2Completed | 17 Dec 2024 | A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy | |
| Phase 1/2Completed | 31 Jan 2015 | An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy | |
| Phase 1Completed | 31 Jan 2013 | An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) | |
| Phase 1Completed | 28 Feb 2014 | An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701) | |
| Phase 1Completed | 31 Jan 2017 | An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026